anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
An apparatus and system for laboratory blood sample ordering, collection, and processing is described. The apparatus and system include a central computer processor, a provider user interface connected to the central computer processor, a test profile database connected to the central computer processor, and a schedule database connected to the central computer processor. An order for a blood laboratory test generates collection parameters based upon test type and the time a result is required. The system generates collection parameters, including a sample reserve fraction sufficient to provide sample for predicted future tests. Test results are communicated to the requesting provider and entered into the patient&#39;s electronic medical record. Additional sample collection is ordered if the sample reserve fraction is insufficient for subsequent requested tests.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a biological information managing system which can properly perform the measurement/management of the biological information of a plurality of subjects.  &lt;P&gt;SOLUTION: When an operation for transferring a measured value to a health apparatus is performed in a communication apparatus, a transmission demand is transmitted to the health apparatus from the communication apparatus (S201). The health apparatus can measure and store the biological information of the plurality of subjects to collectively transmit the measured values, which have not been transmitted, regarding all subjects while correlating the measured values with the memory IDs of the storage regions in response to the subjects in which the measured values have been stored, and the serial numbers of the health apparatus in response to the demands (S203). Then, the data is transferred to a server (S205). In the server, the storage region is specified from the correlated memory ID and serial number for each measured value (S207), and the data is stored in the applicable region (S211).  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a stable skin lotion capable of forming a uniform film on skin when coated and organoleptically excellent by including a complex comprising a ceramide, a phospholipid and cholesterol and a polyhydric alcohol. SOLUTION: This skin lotion is obtained by including (A) &gt;=0.01 wt.% of a complex comprising a ceramide, a phospholipid and cholesterol and (B) a polyhydric alcohol in an amount of 10-100 times based on the ingredient A. N-Stearoylphytosphingosine, etc., can be used as the ceramide of the ingredient A and the content of the ceramide in the complex is preferably 20-40 wt.%. Sphingomyelin, soybeans, etc., can be used as the phospholipid in the ingredient A. The amount thereof in the complex is preferably 35-70 wt.%. Dipropylene glycol, etc., are cited as the ingredient B and the amount thereof formulated in the skin preparation for external use is preferably 1-40 wt.%. An ointment, a cream, a lotion, etc., are cited as the form of use of the skin preparation for external use.
&lt;P&gt;PROBLEM TO BE SOLVED: To deal with the limit of the present heart transplantation therapy existing in cardiac disease remedy.  &lt;P&gt;SOLUTION: Muscle cells and methods for using the muscle cells are provided. In one embodiment, the invention provides transplantable skeletal muscle cell compositions and methods of their use. In one embodiment, the muscle cells can be transplanted into patients having disorders characterized by insufficient cardiac function, e.g., congestive heart failure, in a subject by administering the myoblasts to the subject. The muscle cells can be autologous, allogeneic, or xenogeneic to the subject. Furthermore, the present invention proposes the modification, masking or removal of antigens existing on the cells in the compositions to inhibit the lysis of the cells, when the compositions are administered to the subject.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To prepare a cosmetic which has an excellent skin unevenness-correcting effect for covering the small wrinkles and pores of the skin, can give a natural finish without deteriorating a bare skin appearance and a transparent appearance, gives a highly good sense of use, and has a highly good effect-retaining property.  &lt;P&gt;SOLUTION: This oily cosmetic is characterized by containing a silicone oil and a silicone-gelling agent as base materials, and further containing (A) silicone powder comprising a crosslinked silicone / a net-like silicone block copolymer, and (B) the powder of a crosslinked polymethyl methacrylate (PMMA). It is preferable that the mass ratio of the silicone powder (A) : PMMA powder is 7 : 3 to 4 : 1. Further, It is preferable that (C) fine titanium dioxide particles are contained in the cosmetic in an amount of 0.01 to 4 mass %. The silicone-gelling agent is preferably a crosslinked organopolysiloxane.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain a stabilizer composition having an improved water solubility, and useful for a medicine and a vciterinary medicine, especially as an anti-ulcer agent. SOLUTION: This stabilizer composition useful for anti-ulcer agent having an improved water solubility contains a benzimidazole-based compound of the formula [A-ring can be substituted; R&lt;b&gt; is H, an alkyl, an acyl, a carbamoyl, an alkoxysulfonyl, etc.; R&lt;c&gt; , R&lt;e&gt; and R&lt;g&gt; are each H, an alkyl, an alkoxy or an alkoxyalkoxy; R&lt;d&gt; is H, an alkyl or the formula-OR&lt;f&gt; ; R&lt;f&gt; is a hydrocarbon; (q) is 0, 1] and a branched cyclodextrin-carboxylic acid or its salt. The composition contains 0.1-20mol of the branched cyclodextrin-carboxylic acid based on 1mol of the compound of the formula.  By using the branched cyclodextrin-carboxylic acid, the stability of the composition is improved and the water solubility of the benzimidazole-based anti-ulcer agent is markedly increased, and since an effect to the living body e.g. an erythrocytolytic action, is small compared with that of β-cyclodextrin, a high safety to the blood is demonstrated. Especially since the decomposition of β-CyD-G2 -COOH, etc., by an acid or a base is extremely little, it has a high safety.
&lt;P&gt;PROBLEM TO BE SOLVED: To prevent multiple acquisition of medical data that are redundantly managed, in a system in which a plurality of medical facilities share the medical data.  &lt;P&gt;SOLUTION: A client terminal 10 generates catalog information indicating the location of medical data managed in an own medical facility, and transmits the catalog information to a medical data management server 60. The medical data management server 60, if a plurality of pieces of catalog information of medical data with same identification information are stored therein, adds priority order to the catalog information. Furthermore, the medical data management server 60, in response to an acquisition request, transmits catalog information to the client terminal 10. The client terminal 10, if a plurality of pieces of catalog information of medical data with identical identification information are received, and acquires medical data based on the catalog information and the added priority order.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
Pyrrolo[1,2-α]benzimidazoles having structural formulae (A), (B) and (C) were prepared as reductive alkylating agents of DNA. In these compounds only the reduced (hydroquinone) form acts as the alkylating agent. DT-diaphorase is the prerequisite two-electron reducing enzyme which carries out the activation process. Depending on the cancer cell line organ and species source, the substrate and inhibition properties of the enzyme can vary widely. Therefore the design of the yujungamycins was to take advantage of subtle differences in the enzyme structure among cancer cell lines. In doing so, cancer- cell- selective drugs were designed possessing outstanding in vivo activity. The 3-substituent influences the reductive activation process and the substituents (amino, acetamido, and carbamido) were placed at this position with varying configuration (R and S). The variation in hydrogen bonding and stereochemistry permits the yujungamycins to recognize DT-diaphorase from select cancer cells resulting in a &#39;magic bullet&#39; directed toward such cells.
b -mercaptoethylamine, or bisethylamine disulphide, or salts thereof, or mixtures of these substances are used for the protection of living organisms against the injurious effects of ionizing radiations containing a - and b -particles, g -rays, x-rays, and neutrons. Thus, an injectable solution comprises b -mercaptoethylamine and a salt thereof dissolved in a solvent, e.g. water or propyleneglycol in proportions yielding a pH of 6-8, the weight of the two solids being 2-20 per cent that of the solution.  The propylene glycol solution, for intra-muscular injection, may contain a local anaesthetic, e.g. benzocaine.  The solutions, which may also contain antibiotics, e.g. aureomycin and dihydrostreptomycin and haemostatics, e.g. semicarbazone of adrenochrome, may be supplied in ampoules containing a gas inert towards the solution.  Otherwise, the solid substances may be put up in soluble capsules, pastilles, suppositories &amp;c. or, for external application, may be made up with an excepient, e.g. based on polyethyleneglycol.
Inventors have synthesized peptides allowing an engagement of intact CD31 molecules on all the healthy endothelial cells and resting blood platelets and leukocytes that can enter in contact with an implanted device. Those cells can therefore receive the &#34;leave-me-alone&#34; signal delivered by the trans-homophilic engagement of CD31, which is essential to maintain the homeostasis in the circulation and vascularized tissues. Thrombotic or life-threatening occurrence of hemorrhagic or thromboembolic complications have impaired the use of endovascular devices. The devices bearing the mimicking peptides of the present invention are rapidly integrated, because they are perceived by blood platelets and leukocytes as a healthy endothelium, a &#34;self&#39; component. Furthermore, their ability to be rapidly endothelialized with a physiologic endothelial cell phenotype also limits platelet and leukocyte activation at the site of device implantation in the long-term. Accordingly, the present invention relates to peptides mimicking the trans-homophilic CD31-CD31 domain 1 and 2 intercellular interaction.
PURPOSE:To obtain an oligopeptide fraction having a predetermined mol.wt. and usable for a desired purpose such as a foaming agent by successively treating an enzyme decomposition product of ungula/horns using a UF membrane and an RO membrane and to recycle RO membrane transmitted matter to enzyme reaction to use the same. CONSTITUTION:An enzyme decomposition product can be treated in a closed system generating no environmental pollution. The enzyme decomposition product is successively treated using a UF membrane and an RO membrane to obtain an oligopeptide fraction devided into desired molecular fractions. This fraction can be used as a foaming compsn. or a cosmetics material. Since Fe&lt;2+&gt; is used in the production of the foaming compsn., the foaming compsn. excellent in foamability and the holding power of an air bubble is obtained. The oligopeptide compsn. with a low mol.wt. transmitted through the RO membrane has a light color and can be used as a cosmetics material as it is. RO membrane transmitted matter is recycled to enzyme reaction to be reutilized and the enzyme decomposition product is effectively treated without bringing about environmental pollution.
PROBLEM TO BE SOLVED: To obtain a medicinal composition capable of stably suppressing the decomposition of a disulfide-based vitamin B1 derivative and a foul smell derived from the compound containing sulfur as a metabolic product without damaging its efficacy, and high in ingesting property. SOLUTION: This medicinal composition contains a disulfide-based vitamin B1 derivative (e.g.; thiaminepropyldisulfide), vitamin B12 &#39; s (e.g.; cyanocobalamine) and a hydroxypropylcellulose having the low extent of a substitution, and further is blended with α-starch. The blending weight ratios is 0.001-0.3 vitamin B12 &#39;s based on 1 disulfide based vitamin B1 derivative, and 0.5-100000 weight ratio of the hydroxypropylcellulose having the low extent of the substitution based on 1 vitamin B12 &#39;s, and the α-starch is blended in a range of (1:0.1)-(1:10) to the hydroxypropylcellulose having the low extent of the substitution. Besides, by suitably blending conventional additives, a solid form oral preparation such as tablets, capsules, granules and powder and a semi-solid preparation such as a pap agent and an ointment are prepared.
PURPOSE:To obtain a smoke generating agent for treating hemorrhoid consisting of moxa capable of generating combustion smoke for treating hemorrhoid by it&#39;s combustion, capable of preventing congestion of vein resulted in hemorrhoid and effective in healing of affected part of hemorrhoid without causing side effects. CONSTITUTION:The aimed agent containing moxa capable of generating combustion smoke for treating hemorrhoid by it&#39;s combustion as a main ingredient. A moxa obtained by drying leaf of Artemisia indica which is a perennial grass of Artemisia and then making the dried leaf linear is used as the moxa. Hemorrhoid is treated by exposing affected part into combustion smoke obtained by burning moxa. The agent can be also applied by rubbing ash after combustion into the affected part. The affected part is nearly completely healed by repeatedly using moxa at an amount of 10g in combustion time of about 15-20min once daily for about 8 day.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to oncology. Donor’s material is grafted. In this case, a blood sample is taken from patient&#39;s radial vein. Plasma rich in platelets is obtained by double centrifugation. Lipoaspiration is performed, the resulting fat cells are mixed with the prepared platelet-rich plasma. After removal of a tumor in a volume that is adequate to the prevalence of the process, the skin is sharply cut according to the marking with formation of skin-fat flaps, they are moved to the place of a postoperative defect. Prepared mixture of plasma rich in platelets and adipose tissue is injected into the subcutaneous fat tissue of the flaps, taking into account the volume of the lost tissue. Prepared flaps replace the formed defect of the eyelids and surrounding tissues. Fixation is carried out with nodular sutures along the edge of the operating wound, suturing the donor zone, applying an antiseptic and applying bandages to the main and donor wounds.EFFECT: method allows to improve the quality of life of patients with malignant tumors of eyelid skin, due to simultaneous elimination of an extensive postoperative defect, which, in its turn, will allow achieving social and labor rehabilitation.1 cl, 1 ex
This study conducted a randomized controlled clinical trial with an intention to enroll 80 insomnia participants. Participants were randomly assigned in a 1:1:1:1 ratio to four groups:1）taVNS combined with slow breathing group；2）taVNS with normal breathing group；3）slow breathing with sham taVNS group；4）normal breathing with sham taVNS group.The study included a one-week baseline period, a two-week treatment period, and a two-week follow-up period. During the 2-week treatment period, 20 minutes of continuous treatment was performed every evening. The stimulation parameters were set to 20Hz, 200μs, 5s ON-5s OFF and a burst frequency of 2000Hz. For taVNS combined with slow breathing group,after preparing the skin, electrodes were attached to the tragus and cymba conchae of the left ear,and under the guidance of the device\&#39;s video, the participants were instructed to perform six slow and relaxed breaths per minute (0.1Hz), while the device delivered stimulation during the 5 seconds of exhalation.For taVNS with normal breathing group,without video guidance on the device, the participants breathed freely while receiving normal taVNS intervention.For slow breathing with sham taVNS group,the participants followed the video instructions to perform slow breathing while wearing the stimulation electrodes, but the device only outputted stimulation for one minute.For normal breathing with sham taVNS group,the device outputted stimulation for only one minute, and the participants breathed normally. EEG and ECG data were collected before and after the 2-week treatment, and scale data were collected before and after the treatment as well as at the end of follow-up. Sleep diaries were recorded throughout the 5-week period.
Physiological sensors may be utilized to obtain physiological data for a user. The sensor data may be utilized in predicting a user&#39;s outcome to a medical intervention using one or more models. The models may be automatically executed in response to receiving certain types and/or amount of data, such as data received from one or more physiological remote sensors, such as Internet of Things sensors. The sensors may include heart rate sensors, arterial pressure sensors, glucose sensors, temperature sensors, weight sensors, blood oxygen sensors, urine sensors, saliva sensors, skin conduction sensors, muscle sensors, brain signal sensors, and/or other sensors. A sensor may communicate over the 2360-2400 MHz and/or the 30-37.5 MHz radio frequency (RF) band. The data may be received from a networked data store. Execution of the models may identify health issues in substantially real time, and the operation of one or more medical devices may be modified and/or a communication may be generated.
PROBLEM TO BE SOLVED: To provide a peptide which has a relatively low mol.wt. and can be used for preventing and treating diseases accompanied of the abnormal production of IL-6. SOLUTION: This IL-6 signal transmission-antagonizing peptide has the following characteristics. (1) The IL-6 signal transmission-antagonizing peptide bound to an IL-6 receptor exhibits an IL-6 function-inhibiting action on the three- dimensional structure. (2) The basic primary structure of the specific three- dimensional structure formation contains a 6 to 9 amino acid sequence whose both ends are nipped with cysteine molecules. (3) The amino acid sequence has a mol.wt. of &lt;=3 kd. The IL-6 signal transmission-antagonizing peptide is an IL-6-binding motif peptide having a human IL-6 signaling-inhibiting action against the human IL-6 receptor.
PURPOSE:To produce the titled microcapsule in high trapping yield of principal drug, by producing a W/O-type emulsion from an oily layer containing a polymer and an aqueous layer containing a specific amount of encephalin, mixing the emulsion with an aqueous solution of a dispersing agent and distilling out the solvent from the resultant emulsion. CONSTITUTION:A W/O-type emulsion is produced from (A) an oily phase containing a polymer having bio-compatibility and hardly soluble or insoluble in water, preferably a polymer having acidic residue (e.g. a polylactic acid, a copolymer of lactic acid and glycolic acid, etc.) and (B) an aqueous layer containing 5-20wt%, preferably 5.0-15.0wt% (based on the polymer) encephalin, its analog or its salt with a weak acid having a pKa of &gt;=4.0, preferably 4.0-9.5 (e.g. acetic acid, propionic acid, etc.). The obtained W/O-type emulsion is mixed with an aqueous solution of a dispersing agent to form a W/O/W-type emulsion. A microcapsule having tough wall membrane effective in suppressing excessive initial release of the content can be produced by distilling the oily layer solvent from the obtained emulsion.
1. A liposomatic vaccine composition comprising an antige or an antige composition, an immunologically active saponin fraction and a sterol, characterized in that ratio of saponin : sterol is from 1:1 to 1:100 (w/w). 2. A vaccine composition according to claim 1 wherein the ratio of saponin : sterol is from 1:1 to 1:5. 3. A vaccine composition according to claim 1 wherein the ratio of saponin : sterol is 1:2 (w/w). 4. A vaccine composition according to any claims 1 to 3, wherein the immunologically active saponin fraction is QS21. 5. A vaccine composition according to any claims 1 to 3, wherein the sterol is cholesterol. 6. A vaccine composition according to any claims 1 to5, which further contains 3D-MPL. 7. A vaccine composition according to any claims 1 to 6, further comprising a carrier, which is aluminum salt or aluminum hydroxide, or emulsion of type &#34;oil in water&#34;. 8. A vaccine composition according to any claims 1 to 7, characterized in that an antigen or antigenic composition derived from any of Human Immunodeficiency Virus, Feline Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma. 9. A vaccine according to any of claims 1 to 7, characterized in that an antigen or an antigen composition are derived from a tumor. 10. A vaccine according to any of claims 1 to 9, characterized in that is used in medicine. 11. Use of liposomatic composition comprising immunologically active saropin fraction and a sterol, characterized in that ratio of saponin : sterol is from 1:1 to 1:100 (w/w) for the manufacture of a vaccine for the prophylactic and/or for the immunotherapeutic treatment of viral, bacterial, parasitic infections or cancer. 12. A method of treating a mammal suffering from or susceptible to a pathogenic infection, characterized in that comprising the administration of a safe and effective amount of a composition according to any of claims 1 to 8. 13. A method of treating a mammal suffering from cancer, characterized in that comprising the administration of a safe and effective amount of a composition according to claim 9. 14. A process for making a vaccine composition according to any claims 1 to 9, characterized in that comprising admixing an immunologically active saponin fraction and sterol, in particular, cholesterol with an antigen or antigenic composition.
PROBLEM TO BE SOLVED: To obtain the subject medicine capable of inhibiting collagen synthesis and treating morbid state of accentuation of cell matrix production by including a pyranopyranone compound as an active ingredient. SOLUTION: This medicine has a compound of formula I [R&#39; is a hexose residue obtained by eliminating OH at 1 position of hexose; R&lt;a&gt; is a group of formula II (R&lt;b&gt; is H, an alkyl, etc.; R&lt;c&gt; and R&lt;d&gt; are each H, an amino-protecting group or R&lt;c&gt; and R&lt;d&gt; together form trimethylene, etc.) or H]. The compound of, formula I includes swertiamarin which is obtained by extracting swertia Herb which is a crude medicine. The medicine has action improving accentuation of collagen synthesis observed in cells attacked by diseases exhibiting morbid state of accentuation of extracellular matrix production, e.g. liver cirrhosis, interstitial lung disease, chfonic renal failure, cardiac hypertrophy, postoperative cicatrix, burn cicatrix, keloid or hypertrophic cicatrix caused after traffic accident, scleroderma, arteriosclerosis or rheumatoid arthritis and effectively can treat the above diseases.